American Society of Hematology Annual Meeting & Exposition

newsroom

News
Research Summaries
Insights
Podcasts Q&As Video

Featured

Conference Coverage
ASH Conference Coverage
Conference Coverage
Mosunetuzumab as a Treatment Option for Patients With Relapsed or Refractory Mantle Cell Lymphoma
12/10/2024
Anthony Calabro, MA
Researchers report on the first safety and efficacy of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for patients with relapsed/refractory Mantle cell lymphoma. This study was presented at...
12/10/2024
Conference Coverage
Person pouring various pills into hand
Conference Coverage
How Effective Is the Ibrutinib-Venetoclax-Obinutuzumab Triplet in Mantle Cell Lymphoma?
12/10/2024
Miranda Manier, BA
The OASIS trial evaluates the efficacy of ibrutinib, venetoclax, and obinutuzumab in newly diagnosed mantle cell lymphoma, reporting a 5-year progression-free survival (PFS) rate of 80% and overall survival...
12/10/2024
Conference Coverage
red blood drop
Conference Coverage
Patients with Mantle Cell Lymphoma Treated With cBTKi With and Without Cytotoxic Chemotherapy
12/09/2024
Anthony Calabro, MA
Researchers analyzed data from a nationwide cohort to evaluate the effectiveness of covalent Bruton tyrosine kinase inhibitors, used either as monotherapy or in combination with anti-CD20 monoclonal...
12/09/2024

Conference Coverage

Conference Coverage
ASH Conference Coverage
Conference Coverage
Mosunetuzumab as a Treatment Option for Patients With Relapsed or Refractory Mantle Cell Lymphoma
12/10/2024
Anthony Calabro, MA
Researchers report on the first safety and efficacy of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for patients with relapsed/refractory Mantle cell lymphoma. This study was presented at...
12/10/2024
Conference Coverage
Person pouring various pills into hand
Conference Coverage
How Effective Is the Ibrutinib-Venetoclax-Obinutuzumab Triplet in Mantle Cell Lymphoma?
12/10/2024
Miranda Manier, BA
The OASIS trial evaluates the efficacy of ibrutinib, venetoclax, and obinutuzumab in newly diagnosed mantle cell lymphoma, reporting a 5-year progression-free survival (PFS) rate of 80% and overall survival...
12/10/2024
Conference Coverage
red blood drop
Conference Coverage
Patients with Mantle Cell Lymphoma Treated With cBTKi With and Without Cytotoxic Chemotherapy
12/09/2024
Anthony Calabro, MA
Researchers analyzed data from a nationwide cohort to evaluate the effectiveness of covalent Bruton tyrosine kinase inhibitors, used either as monotherapy or in combination with anti-CD20 monoclonal...
12/09/2024
Conference Coverage
Doctor reviewing a file with a patient
Conference Coverage
Is Outpatient Administration of Brexucabtagene Autoleucel Safe for Patients With Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma?
12/09/2024
Miranda Manier, BA
A retrospective study highlights the safety and feasibility of outpatient administration of brexucabtagene autoleucel for patients with acute lymphoblastic leukemia and mantle cell lymphoma, showing...
12/09/2024
Conference Coverage
cc
Conference Coverage
Venetoclax-Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Improves PFS Compared With Venetoclax Alone
02/23/2024
Anthony Calabro, MA
Researchers assessed the efficacy of venetoclax-based treatments for patients with relapsed/refractory chronic lymphocytic leukemia. This study was presented at the 65th ASH Annual Meeting & Exposition...
02/23/2024

Clinical Insights

Podcast
Nirmish R. Shah, MD
Podcast
The Use of Patient-Reported Outcomes to Assess Symptom Burden in Sickle Cell Disease
08/06/2024
Nirmish R. Shah, MD
In this podcast, Nirmish Shah, MD, discusses patient involvement and the use of patient-reported outcomes in the development of sickle cell disease interventions. Dr Shah’s team presented research on this...
08/06/2024
Video
Diana Abbott
Video
Treatment Outcomes in Elderly Patients Receiving First Line Therapy for Diffuse Large B-Cell Lymphoma
04/08/2024
Diana Abbott, PhD; Grace Bosma, MS
In this video, Diana Abbott, PhD, and Grace Bosma, MS, discuss their team’s study on the outcomes and intensity of first-line therapy for the treatment of diffuse large B-cell lymphoma (DLBCL) in elderly...
04/08/2024
Conference Coverage
Nirmish R. Shah, MD
Conference Coverage
Use of Machine Learning to Predict Outcomes in Patients With Sickle Cell Disease Treated for Vaso-Occlusive Crisis
01/09/2024
Nirmish R. Shah, MD
In this podcast, Nirmish Shah, MD, discusses using machine learning and leveraging data analysis to make patient predictions about pain and readmission, to use interventions to minimize complications. Dr...
01/09/2024
Conference Coverage
Pinkal Desai, MD
Conference Coverage
Impact of Chemotherapy, Radiation in Patients Who Develop Acute Myeloid Leukemia, Myelodysplastic Syndrome
12/29/2023
Pinkal Desai, MD
In this podcast, Pinkal Desai, MD, discusses the impact of previous chemotherapy and/or radiation exposure in patients who go on to develop acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS),...
12/29/2023
Conference Coverage
Nirmish R. Shah, MD
Conference Coverage
Use of AB1 to Upregulate Fetal Hemoglobin in Patients With Sickle Cell Disease
12/22/2023
Nirmish R. Shah, MD
In this podcast, Nirmish Shah, MD, discusses an overview, the results, and the preclinical and clinical impact of the study titled Preclinical and Clinical Use of AB1, a DNMT1 Protein Depleter, to...
12/22/2023